Tumor News and Research

RSS

Neutrophil reprogramming promotes tumor growth in certain cancers

A new research study led by A*STAR.Singapore Immunology Network (A*STAR.SIgN) has found that neutrophils - one of the most abundant white blood cells in our body - change drastically in certain cancers, adopting a new function whereby they promote tumour growth.

23 Feb 2024

How did COVID-19 impact cancer incidence trends in the US?

Cancer rate patterns from March to December 2020.

23 Feb 2024

Off-the-shelf cancer vaccine shows promising results in patients with KRAS-mutated tumors

Samara Rahman, 74, considers herself lucky. She gets to take walks on the beach, go swimming and ride her bike - all things that were taken from her when she was diagnosed with pancreatic cancer in November of 2022.

22 Feb 2024

Natural killer cells lead the charge in cancer treatment innovation

Review synthesizes research on NK cells' role in cancer immunity and their potential in therapeutics through bioengineering, immune checkpoint inhibitors, and cell engagers, highlighting ongoing preclinical and clinical trials.

22 Feb 2024

Elevated IFN-γ levels linked to long COVID, study finds

Researchers find elevated IFN-γ levels in long COVID patients, with symptom improvement correlating with decreased IFN-γ, suggesting it as a potential biomarker and target for therapeutic intervention.

22 Feb 2024

New immunotherapy target activin receptor 1C shows promise against cancer

Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

22 Feb 2024

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe switch platform and the GoCAR platform.

22 Feb 2024

$Evaluating the efficacy of ultrahypofractionated whole breast irradiation in a FAST-Forward randomized trial$

Evaluating the efficacy of ultrahypofractionated whole breast irradiation in a FAST-Forward randomized trial

The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast irradiation (WBI, 26 Gy in five fractions over 1 week) was just as effective as the 3-week regimen for local control.

22 Feb 2024

Study reveals unexpected link between cell membrane damage and cellular senescence

Our cells are surrounded by a fragile membrane that's only 5 nanometers thick, 1/20 of a soap bubble. Cells are easily damaged by physiological activities, including muscle contraction and tissue injury.

22 Feb 2024

Can dietary patterns impact stomach cancer risk?

Eating patterns and indices related to gastric cancer and explored their association with stomach cancer risk.

22 Feb 2024

Scientists discover the Achilles heel of chemotherapy-resistant ovarian cancer

Women diagnosed with ovarian cancer may initially respond well to chemotherapy, but the majority of them will develop resistance to treatment and die from the disease.

21 Feb 2024

Vitamin D3 and phytochemicals team up for immune boost and aging defense, study finds

Review highlights the synergistic effects of vitamin D3 and phytochemicals in promoting immune balance, reducing inflammation, supporting gut health, and combating aging, emphasizing the importance of these nutrients for longevity and vitality.

21 Feb 2024

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

21 Feb 2024

Breakthrough research on glioma progression wins BIAL Award in Biomedicine

A team of researchers from Germany, the USA, the UK, and Norway won the third edition of the BIAL Award in Biomedicine, a 300,000 Euro prize promoted by the BIAL Foundation, which seeks to recognize a work in biomedicine of exceptional quality and scientific relevance published in the last ten years.

21 Feb 2024

Rising incidence and mortality rate of hepatocellular carcinoma in the USA: A comprehensive analysis

Over the past two decades, there has been a significant increase in the incidence of primary liver cancer in the USA, with higher rates observed in men.

21 Feb 2024

Study reveals mechanism of drug targeting protein modification in tumor suppressor genes

Researchers have revealed the mechanism of a drug shown to be effective in treating certain types of cancer, which targets a protein modification silencing the expression of multiple tumor suppressor genes.

21 Feb 2024

Lactocore Group leverages milk peptides to combat inflammaging

...

From Lactocore Group 21 Feb 2024

Pioneering cell-based treatment for melanoma offered at Siteman Cancer Center

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.

20 Feb 2024

Novel treatment strategy shows promise against common liver cancer in children

Hepatoblastoma (HB) is the most common liver cancer in children. Researchers and physicians in the field are concerned because in the last decade HB has been rising rapidly worldwide and has seen the most rapid increase among all pediatric solid tumors.

20 Feb 2024

Aging alters fibroblasts to promote pancreatic cancer growth

Older people may be at greater risk of developing pancreatic cancer and have poorer prognoses because of age-related changes in cells in the pancreas called fibroblasts, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

20 Feb 2024